Education
About Us
Working with TipRanks
Follow Us
ExpreS2ion Biotech Holding AB (SE:EXPRS2)
:EXPRS2
RESEARCH TOOLSreports
Top Page
ExpreS2ion Biotech Holding AB
(Frankfurt:EXPRS2)
40Underperform
ExpreS2ion Biotech Holding AB (EXPRS2) vs. S&P 500 (SPY)
Market Cap
kr51.84M
Dividend YieldN/A
Average Volume (3M)6.24K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth-57.26%
EPS Growth72.71%
CountrySE
Employees30
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-18.94
Shares Outstanding2,658,346
10 Day Avg. Volume4,458
30 Day Avg. Volume6,241
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
ExpreS2ion Biotech Holding AB Business Overview & Revenue Model
Company DescriptionExpreS2ion Biotech Holding AB (EXPRS2) is a biotechnology company focused on the development and commercialization of innovative technologies and products within the biopharmaceutical industry. The company specializes in protein production, utilizing its proprietary ExpreS2 platform, which is based on Drosophila S2 cells for the efficient and scalable expression of recombinant proteins. ExpreS2ion Biotech serves sectors such as vaccine development, diagnostics, and therapeutic protein production, providing solutions to both research institutions and the pharmaceutical industry.
How the Company Makes MoneyExpreS2ion Biotech Holding AB generates revenue through several streams, primarily by licensing its proprietary protein expression technology, the ExpreS2 platform, to pharmaceutical companies and research organizations. This licensing can involve upfront payments, milestone payments, and royalties based on the success of the products developed using their technology. Additionally, the company offers contract research services, where they undertake specific projects for clients, which also involves service fees. Partnerships with other biotech and pharmaceutical companies further contribute to its earnings, where collaborative research and development efforts can lead to shared revenue from co-developed products. The company may also receive funding from grants or research initiatives, contributing to its financial inflow.
ExpreS2ion Biotech Holding AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 3.01M | 7.05M | 5.09M | 12.23M | 5.26M | Gross Profit |
| -2.67M | 3.40M | 5.00K | 4.72M | -843.00K | EBIT |
| -67.69M | -105.97M | -127.61M | -48.40M | -31.20M | EBITDA |
| -42.20M | -102.45M | -124.49M | -46.38M | -28.47M | Net Income Common Stockholders |
| -36.41M | -91.40M | -118.61M | -43.92M | -31.71M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 81.54M | 57.60M | 110.97M | 138.88M | 106.83M | Total Assets |
| 104.53M | 78.69M | 137.36M | 151.96M | 118.86M | Total Debt |
| 360.00K | 1.71M | 1.85M | 1.92M | 2.38M | Net Debt |
| -81.18M | -55.89M | -109.12M | -35.19M | -104.45M | Total Liabilities |
| 40.11M | 13.33M | 34.04M | 11.61M | 24.31M | Stockholders Equity |
| 64.42M | 65.36M | 103.33M | 140.35M | 94.55M |
| Cash Flow | Free Cash Flow | |||
| -34.80M | -102.90M | -100.00M | -46.36M | -19.06M | Operating Cash Flow |
| -33.93M | -100.89M | -99.61M | -45.65M | -18.18M | Investing Cash Flow |
| 21.27M | -2.02M | 105.33M | -100.92M | -1.08M | Financing Cash Flow |
| 34.87M | 47.84M | 61.46M | 74.55M | 123.38M |
ExpreS2ion Biotech Holding AB Technical Analysis
Negative
18.98
Price Trends
23.52
Negative
23.72
Negative
29.32
Negative
Market Momentum
-1.16
Negative
38.39
Neutral
46.57
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:EXPRS2, the sentiment is Negative. The current price of 18.98 is below the 20-day moving average (MA) of 20.02, below the 50-day MA of 23.52, and below the 200-day MA of 29.32, indicating a bearish trend. The MACD of -1.16 indicates Negative momentum. The RSI at 38.39 is Neutral, neither overbought nor oversold. The STOCH value of 46.57 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:EXPRS2.
ExpreS2ion Biotech Holding AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $5.31B | 3.33 | -39.82% | 2.92% | 17.95% | 1.84% | |
49 Neutral | kr46.73M | ― | -47.01% | ― | -94.12% | -25.83% | |
44 Neutral | €77.76M | ― | -96.58% | ― | 30.02% | -3985.71% | |
41 Neutral | kr50.72M | ― | -59.73% | ― | ― | 45.38% | |
40 Underperform | kr51.84M | ― | -55.51% | ― | -57.26% | 72.71% | |
36 Underperform | kr71.73M | ― | -85.93% | ― | 58.72% | 70.69% | |
35 Underperform | kr46.00M | ― | -152.99% | ― | ― | 58.36% |
* Healthcare Sector Average
Performance Comparison
SE:EXPRS2
ExpreS2ion Biotech Holding AB
19.40
-74.26
-79.29%
SE:COMBI
CombiGene AB
2.41
-1.36
-36.07%
SE:MODTX
Modus Therapeutics Holding AB
1.28
0.31
32.23%
SE:ONCOZ
OncoZenge AB
4.28
0.39
9.88%
SE:SPAGO
Spago Nanomedical AB
0.22
-0.14
-39.17%
SE:SPRINT
Sprint Bioscience AB
0.66
-0.61
-47.95%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.